#Pharmaceuticals #Investment #EndocrineDiseases
www.benzinga.com
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock - Crinetics Pharmaceuticals (NASDAQ:CRNX)
SAN DIEGO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) ("Crinetics"), a pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, announced today that it intends to offer and sell, subject to market and other conditions, $350.
S
#Pharmaceuticals #EndocrineDiseases #ClinicalTrials
www.streetinsider.com
Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia
SAN DIEGO, Jan. 04, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that the company will host a conference call and webcast on Monday, January 5, 2026 at 8:30 a.
#Pharmaceuticals #ClinicalTrials #EndocrineDiseases
www.benzinga.com
Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia - Crinetics Pharmaceuticals (NASDAQ:CRNX)
SAN DIEGO, Jan. 04, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), today announced that the company will host a conference call and webcast on Monday, January 5, 2026 at 8:30 a.
